Journal article
Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases
Abstract
BackgroundIn the INBUILD trial in patients with chronic fibrosing interstitial lung diseases (ILDs) and a progressive phenotype, nintedanib reduced the rate of ILD progression with adverse events that were manageable for most patients. We investigated the potential impact of immunomodulatory therapies on the efficacy and safety of nintedanib.MethodsSubjects with fibrosing ILDs other than idiopathic pulmonary fibrosis, who had shown progression …
Authors
Cottin V; Richeldi L; Rosas I; Otaola M; Song JW; Tomassetti S; Wijsenbeek M; Schmitz M; Coeck C; Stowasser S
Journal
Respiratory Research, Vol. 22, No. 1,
Publisher
Springer Nature
Publication Date
December 2021
DOI
10.1186/s12931-021-01668-1
ISSN
1465-9921